FDA Panel Says No to Experimental ALS Drug
THURSDAY, Sept. 28, 2023 -- An advisory panel to the U.S. Food and Drug Administration on Wednesday voted resoundingly against recommending a stem cell-based experimental treatment for amyotrophic lateral sclerosis (ALS).
Although the FDA is not...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: ALS | Food and Drug Administration (FDA) | Pharmaceuticals | Stem Cell Therapy | Stem Cells